Itraconazol Stada

Itraconazole, the active ingredient in Itraconazol Stada, is an azole antifungal presented as an oral dosage form for systemic use. It treats a range of superficial and systemic fungal infections in adult patients, including onychomycosis, candidiasis and invasive mycoses. GNH USA supplies Itraconazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is an azole antifungal that targets a broad spectrum of fungal diseases. - Systemic mycoses: effective for blastomycosis, histoplasmosis, aspergillosis and other deep fungal infections. - Onychomycosis: clears fungal nail infections by eradicating the causative dermatophytes. - Candidiasis: resolves mucosal and invasive Candida infections, including oropharyngeal and esophageal forms.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Rash: skin irritation or mild erythema. - Taste disturbance: altered taste perception. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Cardiac failure: worsening of pre‑existing heart conditions. - QT prolongation: potential arrhythmia risk. - Anaphylaxis: rare but life‑threatening allergic response. - Severe liver injury: jaundice, hepatic failure.

Itraconazol Stada requires careful clinical monitoring to minimize risks. - Liver function monitoring: obtain baseline tests and repeat periodically during therapy. - Drug interaction review: assess concomitant medications for CYP3A4 involvement. - Cardiac risk assessment: avoid in patients with existing heart failure. - Pregnancy considerations: prescribe only when benefits outweigh potential fetal risks. - Renal impairment: evaluate need for dose adjustment in severe kidney disease. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Itraconazol Stada may interact with several medicines; clinicians should evaluate each combination. Major Interactions (Avoid): - Rifampin: induces metabolism, markedly reducing itraconazole exposure. - Ketoconazole: additive hepatotoxic potential when co‑administered. - St. John's Wort: strong CYP3A4 inducer, decreasing itraconazole levels. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may increase itraconazole concentrations. - CYP3A4 substrates (e.g., statins, calcium channel blockers): monitor for toxicity. - Warfarin: itraconazole can enhance anticoagulant effect, requiring INR surveillance.